Targeted therapy: Targeting specific molecular targets of LMS, such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), etc (6–8), the utilization of corresponding targeted drugs (such as evacizumab, arotinib, pazopanib, etc) may aid in controlling tumor growth (7, 9, 10). The gene discussed is PDGFRB; the disease is neoplasm.